A groundbreaking gene therapy designed for lung cancer, which genetically alters a patient’s lung cells, is moving closer to potential approval following encouraging clinical trial outcomes. This innovative approach aims to modify cells directly within the lungs to enhance their cancer-fighting capabilities.
The experimental treatment has demonstrated that it can indeed lead to tumor shrinkage. “Very encouragingly, the hypothesis was proven – that there was actually shrinkage of the tumours in the lungs,” stated Wen Wee Ma from Cleveland Clinic in Ohio during a recent American Society of Clinical Oncology meeting in Chicago.
A key feature of this therapy is its use of a modified virus to deliver immune-boosting genes into lung cells. Unlike traditional gene therapies that typically focus on replacing defective genes, this method empowers existing cells to combat tumors more effectively. The delivery mechanism itself is also distinctive.
Cancer treatment is often administered through swallowing or injection. This new therapy, however, is inhaled. “It’s such a different way of giving anti-cancer treatment,” noted Ma. The significant benefit of this inhalation delivery is its direct access to the lungs.
Lung cancer’s status as the deadliest form of the disease is partly due to the challenges in getting treatments to the lungs when administered orally or intravenously. This novel delivery method bypasses some of those systemic limitations.
How the Therapy Works
The treatment employs a herpes virus that has been rendered harmless and non-contagious. Its purpose is to transport two specific genes into lung cells. One gene codes for the protein interleukin-2, and the other for interleukin-12.
These proteins are naturally present in the body and play a role in suppressing tumor growth. However, tumors can often evade these natural defenses and deplete these crucial proteins. The gene therapy aims to re-establish their production within the lung cells, thereby bolstering the immune system’s anti-cancer response.
Clinical Trial Details and Results
Since 2024, Dr. Ma and his colleagues have been evaluating this gene therapy in patients with advanced lung cancer. These individuals had previously exhausted all other treatment avenues. The administration process involves nebulizing a liquid containing the gene therapy, transforming it into a fine mist that patients inhale directly into their lungs via a specialized device.
At the oncology conference, Ma reported that the gene therapy successfully reduced lung tumor size in three out of eleven participants. For an additional five patients, the therapy halted tumor progression. While some patients experienced side effects such as chills or vomiting, no serious safety concerns were identified during the trials.
Regulatory Fast-Tracking and Future Directions
These positive findings have led to the gene therapy receiving “regenerative medicine advanced therapy designation” from the U.S. Food and Drug Administration. This designation signifies the agency’s commitment to expediting the approval process, aiming to make the treatment accessible to patients as quickly as possible.
A current limitation of this gene therapy is its effectiveness primarily against tumors confined to the lungs. It does not address cases where the cancer has metastasized to other parts of the body.
To broaden its application, Ma and his team are exploring the therapy’s use in combination with existing immunotherapies and chemotherapies. These ongoing trials are expected to involve approximately 250 patients, further investigating the therapy’s potential in a more comprehensive treatment approach.
Broader Applications and Company Background
Krystal Biotech, the company behind this inhalable gene therapy, has a track record in developing similar innovative treatments. They previously established the first approved gene therapy for topical application, which is rubbed into the skin. This skin therapy also utilizes the same modified herpes virus to deliver collagen genes to patients with a rare blistering skin condition known as recessive dystrophic epidermolysis bullosa, aiding in skin repair.
The company’s research and development efforts are not limited to lung cancer. Krystal Biotech is also pursuing the creation of inhalable gene therapies for other respiratory conditions, including cystic fibrosis and alpha-1 antitrypsin deficiency, a genetic lung disorder.